Lumicell Diagnostics

Wellesley, United States Founded: 2008 • Age: 18 yrs
Developer of fluorescence-guided imaging technologies to help surgeons detect residual cancer tissue during operations
Annual revenue - Latest available
Total funding $360.8M 18 rounds
Employees 23 Tracked headcount
Investors 4 Known backers
Products 3 Services tracked
Competitors 9 Brand Intelligence

About Lumicell Diagnostics

Lumicell Diagnostics is a company based in Wellesley (United States) founded in 2008 by Moungi Bawendi and W David Lee. Lumicell Diagnostics has raised $360.8 million across 18 funding rounds from investors including HHS, LaunchCapital and BlueIO. The company has 23 employees as of December 31, 2023. Lumicell Diagnostics offers products and services including LumiSystem, LUMISIGHT, and Lumicell DVS. Lumicell Diagnostics operates in a competitive market with competitors including Averto Medical, On Target Laboratories, Huake Precision (Beijing) Medical Technology, C-RAD and US Medical Innovations, among others.

  • Headquarter Wellesley, United States
  • Employees 23 as on 31 Dec, 2023
  • Founders Moungi Bawendi, W David Lee
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
Operational Areas
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $360.8 M (USD)

    in 18 rounds

  • Latest Funding Round
    $198.13 M (USD), Series D

    Apr 22, 2025

  • Investors
    HHS

    & 3 more

  • Employee Count
    23

    as on Dec 31, 2023

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Lumicell Diagnostics

Lumicell Diagnostics offers a comprehensive portfolio of products and services, including LumiSystem, LUMISIGHT, and Lumicell DVS.

Product name locked
Category locked
Primary

Real-time system for detecting residual breast cancer during lumpectomy.

Product name locked
Category locked
Locked

Agent that illuminates cancer for intraoperative visualization.

Product name locked
Category locked
Locked

Technology for real-time cancer excision guidance in surgery.

People of Lumicell Diagnostics

Headcount 10-50
Employee Profiles 6
Board Members and Advisors 10
Employee Profiles
People
Kevin Hershberger
President & CEO
People
W. David Lee
President & Chief Scientific Officer
People
Elisabeth Carroll
Vice President Human Resources
People
Daniel K. Harris
VP of Pharmaceutical Development & CMC

Unlock access to complete

Funding Insights of Lumicell Diagnostics

Lumicell Diagnostics has successfully raised a total of $360.8M across 18 strategic funding rounds. The most recent funding activity was a Series D round of $198.13 million completed in April 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Lumicell Diagnostics

Lumicell Diagnostics has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, LaunchCapital and BlueIO.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
VC firm investing in seed & early stage companies in the US
Locked Locked Locked
Investments are made by BlueIO in early-stage technology companies.
Locked Locked Locked
Public health and human services are overseen by HHS.
Locked Locked Locked
Premium access

Investor details for Lumicell Diagnostics

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Lumicell Diagnostics

Investments
Premium access

Investment portfolio details for Lumicell Diagnostics

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Lumicell Diagnostics

Premium access

Detailed financials for Lumicell Diagnostics

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Lumicell Diagnostics Comparisons

Lumicell Diagnostics Primary company
Description
Developer of fluorescence-guided imaging technologies to hel...
Location
Wellesley, United States
Founded Year
2008
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
23
As of 2023
Premium access

Peer comparison for Lumicell Diagnostics

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Lumicell Diagnostics

Lumicell Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Averto Medical, On Target Laboratories, Huake Precision (Beijing) Medical Technology, C-RAD and US Medical Innovations, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Medical devices for gastrointestinal disease patients are developed.
Locked Locked Locked
Molecular imaging agents for cancer surgery are developed.
Locked Locked Locked
Neurosurgery robots are provided for neurological disorder treatments.
Locked Locked Locked
Oncology treatments are delivered through standalone clinics.
Locked Locked Locked
Electrosurgery and plasma technology for cancer treatment are developed.
Premium access

Detailed competitors of Lumicell Diagnostics

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Lumicell Diagnostics

Premium access

Complete news archive for Lumicell Diagnostics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Lumicell Diagnostics

Lumicell Diagnostics was founded in 2008 and raised its 1st funding round 2 years after it was founded.

Lumicell Diagnostics is headquartered in Wellesley, United States. It is registered at Wellesley, Massachusetts, United States.

Howard Hechler is the current CEO of Lumicell Diagnostics.

Lumicell Diagnostics is a funded company, having raised a total of $360.8M across 18 funding rounds to date.

As of Dec 31, 2023, the latest employee count at Lumicell Diagnostics is 23.

Lumicell Diagnostics was established in 2008 in Wellesley, United States, within the medical imaging sector. Fluorescence-guided systems are created to support surgeons in visualizing residual cancer tissue in real time during operations. Single-cell detection capabilities are integrated, enabling evaluation of the tumor bed after initial resection. Operations focus on oncology applications, with potential to lower recurrence rates and limit needs for follow-up radiation or chemotherapy.

Lumicell Diagnostics's top competitors include Huake Precision (Beijing) Medical Technology, Averto Medical and On Target Laboratories.

Lumicell Diagnostics offers LumiSystem, LUMISIGHT, and Lumicell DVS.

Lumicell Diagnostics has 4 investors. Key investors include HHS, LaunchCapital, BlueIO, and National Science Foundation.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available